Speaker
Summary
The Okayama University Neutron Therapy Research Center (NTRC) was established in April 2017 as a hub for research and education in Boron Neutron Capture Therapy (BNCT). Its primary focus is on the development of BNCT, including the improvement of boron agents, the advancement of irradiation technologies and neutron sources, and the refinement of treatment planning systems. Through activities ranging from basic research to clinical applications, the center aims to establish innovative radiation therapies. Internationally, NTRC has signed a cooperation agreement with the International Atomic Energy Agency (IAEA), and in 2022, Okayama University was designated as an IAEA Collaborating Centre in the field of BNCT, contributing to education, human resource development, and research standardization. In addition, by strengthening partnerships with universities and research institutes in Japan and abroad, the NTRC plays a key role as an international hub for BNCT research.
Our research highlights include the development of innovative BNCT modalities such as transurethral BPA delivery for refractory bladder cancer and boron neutron capture immunotherapy for melanoma in combination with immune checkpoint inhibitors. In parallel, we are synthesizing next-generation boron agents—targeting brain, breast, pancreatic, and gastrointestinal tumors—through strategic collaboration with pharmaceutical sciences. These isotopic agents demonstrate enhanced tumor selectivity and therapeutic efficacy, accelerating the transition from bench to bedside. To strengthen translational predictivity, we have established patient-derived 3D culture models that reproduce the tumor microenvironment with high fidelity. These models not only improve the biological reproducibility of radiation evaluation but also contribute to global efforts to reduce animal testing, aligning with emerging regulatory frameworks on alternative preclinical models.
By linking isotope-based science, translational research, and education, NTRC is shaping BNCT as a paradigm of next-generation precision radiotherapy, contributing both to scientific innovation and to the sustainable development of global healthcare capacity.
| Are you interested/eligible for the Young Session? | No, I am not eligible |
|---|
